The cells need help, and the help needs to be biological
In Geneva, researchers have fashioned a material from placental tissue — ordinarily discarded at birth — into a scaffold that keeps transplanted insulin-producing cells alive inside a diabetic body. The work addresses a failure that has haunted cell transplantation for decades: the twin forces of immune rejection and inadequate blood supply that quietly starve grafts before they can take hold. In diabetic mice, the approach sustained normal blood sugar for the full length of the study, pointing toward a more honest reckoning with what transplanted cells actually need to survive.
- Type 1 diabetes patients face a cruel paradox — the cells that could free them from insulin injections almost always die once transplanted, leaving a promising therapy perpetually out of reach.
- The core killers of transplanted islets are well understood but hard to solve: the immune system attacks foreign tissue while poor blood supply starves cells before they can establish themselves.
- The Geneva team pre-builds a tiny vascular network inside the gel before implantation, giving the graft a circulatory head start the moment it enters the body.
- In diabetic mice, grafts using Amniogel with vessel-forming cells outperformed every control condition, maintaining normal blood sugar for over 100 days without failure.
- The path to human trials remains blocked by scale — a mouse graft is a fraction of what a human patient requires, and manufacturing Amniogel at that volume is unproven.
- This is not a cure, but it is the clearest mechanistic progress toward a bioartificial pancreas that solves the real problems rather than hoping cells will simply endure.
In a Geneva laboratory, researchers have built a gel from human amniotic membrane — the tissue lining the placenta, normally discarded after birth — that keeps transplanted insulin-producing cells alive inside a diabetic body. Called Amniogel, the material addresses what has long made islet transplantation a graveyard of failed attempts: the immune system attacks the foreign cells, and the blood supply where they are placed is too poor to sustain them. When the Geneva team mixed pancreatic islets with vessel-forming cells and suspended them in Amniogel, the construct began building its own microvascular network before it ever entered the body. Once implanted into diabetic mice, that network connected to the host's circulation — and the grafts maintained normal blood sugar for at least 100 days, the full length of the study.
Type 1 diabetes destroys the beta cells that produce insulin, and replacing them is theoretically straightforward. In practice, donor tissue is scarce, immune rejection is relentless, and even the liver — the standard implantation site — offers a hostile, inflamed environment. Standard transplants sometimes work for years, but the graft eventually fails and patients return to injections. Amniogel attempts to change the underlying conditions rather than simply placing cells and hoping. The material mimics the natural environment islets lose the moment they are isolated from the pancreas, providing structural support and chemical signals that help the cells settle rather than struggle. Laboratory testing also suggested the gel slows the movement of immune cells toward the graft, though the researchers stop short of claiming it resolves rejection.
The work remains early. A mouse graft is tiny; a human patient requires far more insulin-producing tissue, and whether Amniogel can be manufactured and deployed at that scale is unanswered. Long-term durability over years, not weeks, is also unproven. But among the many attempts to build a functional bioartificial pancreas, this approach is notable for confronting the actual mechanisms that kill transplants rather than working around them. It is not close to patients yet — but it represents a more grounded path forward than the field has often had.
In a laboratory in Geneva, researchers have engineered a gel that does something the field has struggled with for decades: keeps transplanted insulin-producing cells alive and working once they're inside a diabetic body. The material, called Amniogel, is made from human amniotic membrane—the tissue that lines the placenta and is normally discarded after birth. When combined with cells that form blood vessels and then implanted into diabetic mice, the grafts maintained normal blood sugar levels for at least 100 days, the full length of the study period. That may not sound remarkable until you understand what usually happens to transplanted pancreatic islets: they fail, often quickly, because the body's immune system attacks them and because they can't access enough blood supply to survive.
Type 1 diabetes destroys the beta cells in the pancreas that produce insulin. Replacing those cells is theoretically elegant—restore the cells, restore blood sugar control. In practice, it has been a graveyard of failed attempts. Donor tissue is scarce. The immune system recognizes the transplanted cells as foreign and attacks them. And even when surgeons place the cells in the liver, where the blood supply is poor and inflammation runs high, the cells wither. Standard islet transplantation works for a time, sometimes years, but eventually the graft fails. Patients end up back on insulin injections.
The Geneva team's approach addresses the most fundamental problem: blood supply. Before transplantation, they mix the pancreatic islets with vessel-forming cells and suspend them in Amniogel. Those vessel-forming cells begin building a network of tiny blood vessels while the construct is still outside the body. Once implanted, that network can connect to the host's own circulation. In the mice, grafts with this engineered vascular network outperformed both standard islet transplants and constructs without the blood vessel engineering. The gel itself appears to offer a secondary benefit: in laboratory testing, it slowed the movement of immune cells that would normally attack the graft, suggesting some early protection from rejection, though the researchers are careful not to claim it solves the immune problem entirely.
Amniogel works because it mimics the natural environment pancreatic islets lose the moment they're isolated from the pancreas. The amniotic membrane provides structural support and chemical signals that help the cells feel less like they've been ripped from their home and dropped into hostile territory. It is a more sophisticated version of what transplant surgeons have always known: the cells need help, and the help needs to be biological, not just mechanical.
This remains early-stage work. The mice lived with functioning grafts for 100 days; humans live for decades. The next hurdle is scale. A single mouse graft is tiny. A human patient needs far more insulin-producing tissue, which means either larger grafts or multiple ones, and the researchers have not yet demonstrated that Amniogel can be manufactured and deployed at that size. There is also the question of long-term durability and whether the immune protection holds up over years, not weeks. But among the various attempts to build a true bioartificial pancreas—one that actually works like a pancreas rather than just being a collection of cells hoping to survive—this approach looks more grounded in solving the actual problems that kill transplants. It is not a cure yet. It is not even close to patients. But it is a clearer path forward than hoping the cells will simply take root and thrive on their own.
Citações Notáveis
The gel provides a more natural environment for pancreatic islets and helps recreate some of the support they lose during isolation— Geneva research team
A Conversa do Hearth Outra perspectiva sobre a história
Why does blood supply matter so much more than we might expect?
Because an islet cell that can't access oxygen and nutrients dies within hours. You can have the perfect cell, but if it's sitting in a pocket of dead tissue with no circulation, it's already gone. The gel solves that by building the blood vessels before you even put the graft in.
So the amniotic membrane itself—that's not doing the heavy lifting?
It's doing something, but it's more like creating the right neighborhood. The real work is the vessel-forming cells. The gel is the environment that lets those cells do their job without the graft being attacked immediately.
Why is immune attack so fast?
The body recognizes the transplanted cells as foreign within minutes. Immune cells swarm in. In a standard transplant, there's nothing between those attacking cells and the islets. The gel slows that process down, buys time for the graft to integrate.
A hundred days in mice—what does that translate to in human time?
We don't know yet. Mouse metabolism is different. But it's long enough to prove the concept works. The real test is whether it lasts years in humans, not weeks.
What happens after the gel breaks down?
That's the question. If the blood vessels have integrated properly, the graft should be self-sustaining. If not, you're back where you started. The researchers haven't published data on that yet.
Why hasn't anyone tried this before?
They have, in different forms. But using amniotic membrane specifically, combined with pre-engineered vasculature—that's newer. It's the combination that seems to work.